AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Butacaine works by blocking nerve signals in the body, thereby temporarily numbing the area where it is applied. This effect helps to reduce pain or discomfort during procedures such as minor surgeries, dental procedures, or the insertion of catheters.
Topical Application: Butacaine is usually applied topically to the skin or mucous membranes, such as the lining of the mouth or the rectal area. It may come in the form of creams, ointments, gels, or sprays for easy application.
Rapid Onset: The combination of butamben and tetracaine in butacaine allows for a rapid onset of anesthesia, providing quick relief from pain or discomfort.
Short Duration: The duration of action of butacaine is relatively short-lived, typically lasting for a few hours. This makes it suitable for minor procedures or temporary relief of pain.
Low Systemic Absorption: When applied topically, the systemic absorption of butacaine is minimal, reducing the risk of systemic side effects. However, absorption may vary depending on factors such
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.6 | |
| ADHD | 0.3 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.4 | 0.7 | -0.75 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alzheimer's disease | 0.6 | 0.9 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Asthma | 0.3 | 0.3 | 0 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 0.9 | 0.3 | 2 |
| Autism | 0.9 | 0.9 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.6 | 0 |
| Brain Trauma | 0.6 | -0.6 | |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 0.3 | 0.6 | -1 |
| Cerebral Palsy | 0.3 | 0.6 | -1 |
| Chronic Fatigue Syndrome | 0.7 | 1 | -0.43 |
| Chronic Kidney Disease | 0.3 | 0.3 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.6 | 0.6 | |
| Colorectal Cancer | 0.6 | 0.3 | 1 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | 0.6 | -1 |
| COVID-19 | 0.6 | 1 | -0.67 |
| Crohn's Disease | 0.9 | 0.9 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.6 | 0.6 | 0 |
| Depression | 0.9 | 1 | -0.11 |
| Eczema | 0 | 0 | |
| Endometriosis | 0.6 | 0.6 | 0 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.4 | -0.4 | |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.9 | 0 |
| gallstone disease (gsd) | 0.4 | 0.4 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Gout | 0.6 | 0.6 | 0 |
| Graves' disease | 0.6 | 0.9 | -0.5 |
| Gulf War Syndrome | 0.3 | 0 | 0 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.6 | 0.3 | 1 |
| Heart Failure | 0.9 | 0.3 | 2 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 0.9 | -0.5 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | |
| Inflammatory Bowel Disease | 0.3 | 1 | -2.33 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 0.6 | 0.9 | -0.5 |
| ischemic stroke | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 0.9 | 0.9 | 0 |
| Long COVID | 0.4 | 1 | -1.5 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.4 | -0.4 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Metabolic Syndrome | 0.9 | 0.9 | 0 |
| Mood Disorders | 0.9 | 1 | -0.11 |
| Multiple Sclerosis | 0.3 | 0.9 | -2 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.9 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 0.9 | 0.9 | 0 |
| obsessive-compulsive disorder | 0.4 | 0.6 | -0.5 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 0.7 | 0.9 | -0.29 |
| Polycystic ovary syndrome | 1 | 0.7 | 0.43 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 0.4 | 0.6 | -0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.6 | 0.67 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 0.9 | 0.9 | 0 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.9 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.6 | -1 |
| Systemic Lupus Erythematosus | 0.6 | 0.3 | 1 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.9 | 0.6 | 0.5 |
| Type 2 Diabetes | 0.9 | 0.9 | 0 |
| Ulcerative colitis | 0.3 | 0.9 | -2 |
| Unhealthy Ageing | 0.6 | 0.3 | 1 |
| Vitiligo | 0.6 | 0.1 | 5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
